San Carlos, CA, United States of America

Maria Fardis

USPTO Granted Patents = 26 

 

 

Average Co-Inventor Count = 4.6

ph-index = 12

Forward Citations = 474(Granted Patents)


Location History:

  • San Carlso, CA (US) (2014)
  • San Carlos, CA (US) (2003 - 2023)

Company Filing History:


Years Active: 2003-2025

Loading Chart...
Loading Chart...
Loading Chart...
26 patents (USPTO):Explore Patents

Title: Maria Fardis: Innovator in Cancer Treatment Patents

Introduction: Maria Fardis, based in San Carlos, California, is a prolific inventor with an impressive portfolio of 25 patents. Her contributions to the field of oncology, particularly in utilizing tumor infiltrating lymphocytes, have significantly advanced treatment methodologies for melanoma, especially in cases resistant to conventional therapies.

Latest Patents: Among her latest innovations, Maria has developed methods for using tumor infiltrating lymphocytes in double-refractory melanoma. This research discloses techniques for treating melanomas that are unresponsive to other forms of therapy. Additionally, she has identified IP-10 as a biomarker to predict treatment efficacy, further enhancing personalized medicine approaches in oncology.

Career Highlights: Maria has an extensive career, having worked with renowned organizations like Gilead Sciences and Kosan Biosciences. Her roles in these companies have allowed her to refine her expertise and contribute significantly to cancer treatment solutions, particularly through her patented inventions.

Collaborations: Throughout her career, Maria has collaborated with notable professionals in the field, including Aesop Cho and Xiaowu Chen. These collaborations have fostered innovation and knowledge exchange, driving forward advancements in cancer therapies.

Conclusion: Maria Fardis continues to be an influential figure in cancer research and patented innovation. Her work not only addresses pressing medical challenges but also enhances treatment options available to patients suffering from double-refractory melanoma. As her career progresses, the scientific community eagerly anticipates her future contributions to the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…